Chapter 15: Overview of Hemostasis and Platelet Physiology

Castellone, Donna
January 2007
Hematology in Practice;2007, p229
Book Chapter
Chapter 15 of the book "Hematology in Practice" is presented. It offers an overview of the systems involved in hemostasis. It traces the history of the study of blood coagulation. It discusses coagulation, its role in hemostasis and the two major systems of hemostasis. It explains the mechanism of vasoconstriction, events following vascular injury, platelet function and kinetics, and classification of coagulation factors. Also included are the common pathway, thrombin formation, and fibrinolysis.


Related Articles

  • Coagulación. Reyes Velászquez, Joel Oma; Ríos Alcántara, José Manuel // Medicina Oral (16656024);2010, Vol. 12 Issue 4, p154 

    No abstract available.

  • Using activated factor VII in ob/gyn practice. Paidas, Michael J.; Rosenman, Stephen; Hossain, Nazli // Contemporary OB/GYN;Oct2007, Vol. 52 Issue 10, p46 

    This article describes the role of activated recombinant FVII (rFVIIa) in blood clotting. This agent acts in two stages and its local effects have profound indirect system effects. rFVIIa exerts an influence on Tissue Factor (TF)-bearing cell surfaces and thrombin-activated platelets. Blood...

  • Ginkgo biloba Extract EGb 761® Shows No Effect on Bleeding Time in Healthy Volunteers. Brown, Donald J. // HerbalGram;Spring2004, Issue 62, p21 

    Presents a study which examined the effects of gingko biloba extract EGb 761 on coagulation and platelet function. Basis of the study; Evaluation of primary hemostasis; Effect of EGb 761 on fibrinolysis and platelet function.

  • Hemostatic Status and Fibrinolytic Response Potential at Different Phases of the Menstrual Cycle. Koh, Stephen C. L.; Prasad, N. V.; Fong, Y. F. // Clinical & Applied Thrombosis/Hemostasis;Jul2005, Vol. 11 Issue 3, p295 

    Coagulation and fibrinolytic variables including platelet function and endogenous fibrinolytic response were determined in 30 normal healthy women volunteers not on any known medication during the period of study. They were between 18 years and 38 years old and had normal menstrual cycles of...

  • Assays of different aspects of haemostasis -- what do they measure? Tynngård, Nahreen; Lindahl, Tomas L.; Ramström, Sofia // Thrombosis Journal;2015, Vol. 13 Issue 1, p1 

    Haemostasis is a complex process affected by many factors including both cellular and plasma components. It is a multistep process starting with platelet adhesion to damaged endothelium and ending in clot fibrinolysis. There are several methods available to study different aspects of haemostasis...

  • The Hemostatic System. Stassen, J. M.; Amout, J.; Deckmyn, H. // Current Medicinal Chemistry;Sep2004, Vol. 11 Issue 17, p2245 

    The hemostatic system comprises platelet aggregation, coagulation and fibrinolysis also termed primary, secondary and tertiary hemostasis. From the platelet transcriptome 6000 mRNA species and represent receptors, ion channels, signalling molecules, kinases, phosphatases, and structural,...

  • Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research. Marx, Pauline F.; Verkleij, Chantal J. N.; Seron, Mercedes Valls; Meijers, Joost C. M. // Mini Reviews in Medicinal Chemistry;Sep2009, Vol. 9 Issue 10, p1165 

    Thrombin-activatable fibrinolysis inhibitor (TAFI) provides an important molecular link between the coagulation and fibrinolytic systems. In this review, recent major advances in TAFI research, including the elucidation of crystal structures, the development of small inhibitors and the role of...

  • Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis. Natorska, Joanna; Bykowska, Ksenia; Hlawaty, Marta; Marek, Grzegorz; Sadowski, Jerzy; Undas, Anetta // Heart;Dec2011, Vol. 97 Issue 24, p2023 

    Background High molecular weight von Willebrand factor (vWF) multimers (HMWM) are often deficient in patients with severe aortic stenosis (AS) owing to shear stress-enhanced proteolysis of vWF. It has also been reported that AS is associated with increased activation of blood coagulation....

  • Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. Escolar, Gines; Fernandez-Gallego, Victor; Arellano-Rodrigo, Eduardo; Roquer, Jaume; Reverter, Joan Carles; Sanz, Victoria Veronica; Molina, Patricia; Lopez-Vilchez, Irene; Diaz-Ricart, Maribel; Galan, Ana Maria // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings. We have evaluated the effectiveness of different factor concentrates at reversing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics